EUVIMEDEUVIMED entdecken
Crossref

Dexamethasone and Diphenhydramine Withdrawal and Quality of Life Assessment in Breast Cancer Patients Receiving Weekly Paclitaxel

Letícia de Jesus Rossato, Larissa Lacerda Gonçalves, Eduardo Bischoff, Facundo Zaffaroni, Gabriela Turra Borges, Isabella Mancio, Laura Brasil Mittmann, Bibiana Liberman Thomé, Gabriela de Azevedo Bastian de Souza, Isabela Semmelmann Maia, Gabriel Prolla

Brazilian Journal of Oncology · 20.05.2026 · 22 (CP)

DOI: 10.1055/s-0045-1814367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 20.05.2026. Verfasst von Letícia de Jesus Rossato und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Maintenance of quality of life (QoL) is an important endpoint in cancer patients. Several studies have demonstrated that chemotherapy in breast cancer patients is related to worsening QoL scores. Taxanes are widely used in breast cancer treatment, and premedication omission in weekly paclitaxel has been evaluated in clinical trials and is a safe strategy. Nowadays there is lack of data if premedication withdrawal can improve QoL given the shortage of studies using a comparative group that keeps premedication. Materials and Methods We evaluated QoL scores in 60 breast cancer patients receiving weekly paclitaxel in 2 comparative groups: one that omitted and another that kept premedication, according to infusion-related reaction. The primary endpoint was the evaluation of QoL scores in both groups through the European Organization for Research and Treatment of Cancer's (EORTC) 30-item Core Quality of Life questionnaire (QLQ-C30) and 23-item Quality of Life Questionnaire–Breast Cancer Module (QLQ-BR23) at weeks 1, 2, 3, 4, 5, 9, and 12 of treatment. The secondary endpoint was the frequency of highest-grade adverse events through the adapted Dexamethasone Symptom Questionnaire in both groups.

Results

According to the QLQ-C30 and the QLQ-BR23, in the 2 groups, QoL showed no statistically significant differences related to premedication omission, neither did the frequency of highest-grade adverse events.

Conclusion

Although the absence of statistical differences in the QoL scores regarding premedication omission, some specific domains seem to deteriorate in patients receiving premedication. Future randomized trials exploring tailored questionnaires with specific domains and visual scales may be more accurate to detect QoL differences related to premedication.

Zitieren

APA

Rossato, L. D. J., Gonçalves, L. L., Bischoff, E., Zaffaroni, F., Borges, G. T., Mancio, I., Mittmann, L. B., Thomé, B. L., Souza, G. D. A. B. D., Maia, I. S., & Prolla, G. (2026). Dexamethasone and Diphenhydramine Withdrawal and Quality of Life Assessment in Breast Cancer Patients Receiving Weekly Paclitaxel. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0045-1814367

Vancouver

Rossato LDJ, Gonçalves LL, Bischoff E, Zaffaroni F, Borges GT, Mancio I, et al. Dexamethasone and Diphenhydramine Withdrawal and Quality of Life Assessment in Breast Cancer Patients Receiving Weekly Paclitaxel. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0045-1814367

BibTeX
@article{Rossato2026,
  author = {Rossato, Letícia de Jesus and Gonçalves, Larissa Lacerda and Bischoff, Eduardo and Zaffaroni, Facundo and Borges, Gabriela Turra and Mancio, Isabella and Mittmann, Laura Brasil and Thomé, Bibiana Liberman and Souza, Gabriela de Azevedo Bastian de and Maia, Isabela Semmelmann and Prolla, Gabriel},
  title = {Dexamethasone and Diphenhydramine Withdrawal and Quality of Life Assessment in Breast Cancer Patients Receiving Weekly Paclitaxel},
  journal = {Brazilian Journal of Oncology},
  year = {2026},
  volume = {22},
  number = {CP},
  doi = {10.1055/s-0045-1814367}
}
Kostenlos starten →